BioCentury | Apr 2, 2012
Clinical News

Spartan RX CYP2C19: Phase II/III data

...The open-label, Canadian Phase II/III RAPID GENE trial in 187 patients showed that Spartan's Spartan RX CYP2C19 test...
...stable angina to be randomly assigned to rapid point-of-care genotyping for CYP2C19 mutations with the Spartan RX CYP2C19...
...Data were published in The Lancet. In 2010, Spartan received CE Mark approval for its Spartan RX CYP2C19...
BioCentury | Jan 3, 2011
Clinical News

Spartan RX CYP2C19 regulatory update

...Spartan received CE Mark approval for its Spartan RX CYP2C19 assay to identify carriers of genetic variants of...
...sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) co-market Plavix. Spartan Bioscience Inc. , Ottawa, Ontario Product: Spartan RX CYP2C19...
BioCentury | Aug 16, 2010
Company News

Spartan Bioscience sales and marketing update

...Spartan launched its Spartan RX CYP2C19 pharmacogenetic test worldwide to identify carriers of genetic variants of the Cytochrome...
Items per page:
1 - 3 of 3